{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:15:06Z","timestamp":1777479306380,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hemophilia A is a rare inherited bleeding disorder. Less than 1% of FVIII level in plasma is classified as severe, 1%\u20135% as moderate, and above 5% as mild disease. The aim of this study is to share clinical and surgical experiences in Hemophilia A with extended half-life (EHL) recombinant FVIII preparations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>A retrospective observational study between 2024 and 2025, inpatient or outpatient follow-up was carried out in the Pediatric Hematology clinic of our university hospital. A total of 18 patients diagnosed with severe FVIII deficiency were included in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The average age of the patients was 8.4 years (min. 20 months\u2014max. 17 years). All patients were male and inhibitor negative severe FVIII deficiecy patients. Patients were numbered as P1-18 respectively. P1, P4, and P8 are 20 months, 3 years, and 4 years old respectively. They were evaluated as previously untreated patients (PUP) with a new diagnosis of severe FVIII deficiency and the other patients were previously treated patients (PTPs). P10 had 2 infected decayed molars and 1 incisor extracted in the same dental session. P13 underwent circumcision operation. P18 had refixation surgery due to a left arm radius and ulna bone fracture, and a cast was applied. All three surgical operations were performed under treatment of recombinant FVIII Efmoroctocog alfa (Ealfa\/Elocta\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) successfully.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efmoroctocog alfa seems to be effective in EHL FVIII replacement therapy and surgical management of hemophilia A. Compared with standard half-life (SHL) FVIII products, EHL FVIII products such as Ealfa have the potential to optimize prophylactic outcomes by decreasing the burden of treatment or increasing the level of bleed protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296251377646","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T15:20:58Z","timestamp":1758554458000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6811-4600","authenticated-orcid":false,"given":"H\u00fcseyin Avni","family":"Solgun","sequence":"first","affiliation":[{"name":"SBU Kanuni Sultan Suleyman Training and Research Hospital, Pediatric Hematology and Oncology, Istanbul, Turkiye"},{"name":"SBU Gaziantep City Hospital, Pediatric Hematolgoy and Oncology, Gaziantep, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Ozay","sequence":"additional","affiliation":[{"name":"SBU Gaziantep City Hospital, Pediatric Hematolgoy and Oncology, Gaziantep, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"e_1_3_3_2_2","article-title":"Gene therapy in haemophilia: liter- ature review and regional perspectives for Turkey","author":"Kavakl\u0131 K","unstructured":"Kavakl\u0131 K, Antmen B, Okan V, et al. Gene therapy in haemophilia: liter- ature review and regional perspectives for Turkey. Ther Adv Hematol. 2022 July;23:13.","journal-title":"Ther Adv Hematol"},{"key":"e_1_3_3_3_2","unstructured":"World Federationof Hemophilia. Reportonthe Annual Global Survey 2016. 2017."},{"key":"e_1_3_3_4_2","article-title":"Extended Half-Life (EHL) coagulation fac- tors: a new era in the management of haemophilia patients","author":"Ar MC","unstructured":"Ar MC, Balkan C, Kavakl\u0131 K. Extended Half-Life (EHL) coagulation fac- tors: a new era in the management of haemophilia patients. Turk J Hematol. 2019 Aug;;36(3):141\u2013154.","journal-title":"Turk J Hematol"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13953"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01124.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1354426"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02617.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6161.469"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01615-w"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102180"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_3_3_16_2","unstructured":"Swedish Orphan Biovitrum AB. Elocta: EU summary of product char- acteristics. 2021. Accessed 10 Sep 2021."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13557"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13088"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14309"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251377646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251377646","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251377646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:23Z","timestamp":1777385123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251377646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"alternative-id":["10.1177\/10760296251377646"],"URL":"https:\/\/doi.org\/10.1177\/10760296251377646","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"10760296251377646"}}